Clinical trials were halted temporarily in 2002, but resumed after regulatory review of the protocol in the US, the United Kingdom, France, Italy, and Germany.
Os ensaios clínicos paráronse temporalmente en 2002, pero reiniciáronse despois de que se revisase a regulación do protocolo en EUA, Reino Unido, Francia, Italia e Alemaña.